2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2892

Statin Treatment in Patients with Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2717

Stf-083010, the Inhibitor of ER Stress Transducer IRE1, Suppresses Rheumatoid Synovitis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2826

Stimulation of Autophagy Reduces Misfolded HLA-B27 in a Rat Model of Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 2209

Stimulation of the Adenosine A2A Receptor (A2AR) Regulates the Expression of Netrin-1 (Ntn1) and Its Receptors (Unc5b, DCC) and Inhibits Wear Particle-Induced Inflammatory Osteolysis in a Model of Joint Prosthesis Loosening

Biology and Pathology of Bone and Joint: Bone Remodeling and Metabolism

9:00AM-11:00AM: Abstract Number: 2747

Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2616

Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2514

Subclinical Reduced Ovarian Reserve in Adult Polymiositis Patients

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2837

Sulfasalazine Comedication: A Predictor of Reduced Long-Term Anti-TNF Switch in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2739

Survival of Etanercept (ETN) Responders after Methotrexate (MTX) Failure When ETN Is Initiated As Mono or Combination Therapy or after MTX Withdrawal from ETN/MTX Combination in Long Standing Rheumatoid Arthritis (RA). a Single Center Retrospective Study

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2588

Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2506

Sustained Improvement in Teratogenic Risk Education in a Pediatric Rheumatology Clinic

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2446

Synovial Fluid Proteins Differentiate Patients with Oligoarticular Juvenile Idiopathic Arthritis Who Are Destined to Extend from Those Who Will Remain Persistent in Course

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2830

Synovial Fluid T Cells of Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy Respond to Salmonella Typhimurium Outer Membrane Protein a and Induces IL17 and IL23 Production By Synovial Fluid Mononuclear Cells

Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology Poster II

9:00AM-11:00AM: Abstract Number: 2803

Systemic Interferon Type I and Type II Signatures Present in Distinct Subsets of Primary Sjögren’s Syndrome: En Route Towards More Selective Targeting

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 2986

Systemic Sclerosis Patients on Intensive Care Unit – Reasons for Admission and Determinants of Outcome

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].